Embryo Gene Editing Ethics Framework EditEthics Deep Dive: When Technology Allows Modifying Human Genes, Who Decides Which Modifications Are Permitted

Since the He Jiankui incident shocked the world in 2018, ethical discussions about human embryo gene editing have never ceased. Technology advances, but governance frameworks consistently lag behind. The World Health Organization officially released the EditEthics ethics framework on July 15, the first international governance standard for human embryo gene editing to receive principled recognition from all 193 member states.

EditEthics classifies embryo gene editing into three levels. Level one is therapeutic editing, referring to repairing gene mutations known to cause severe genetic diseases such as thalassemia, Huntington's disease, and cystic fibrosis. This type of editing is deemed ethically acceptable but requires individual approval from nationally designated ethics committees.

Level two is preventive editing, referring to reducing an individual's risk of developing a specific disease, such as removing BRCA1 gene mutations to lower breast cancer risk. This requires stricter risk-benefit assessment and is limited to situations where no other preventive measures are available.

Level three is enhancement editing, referring to modifying gene characteristics unrelated to disease, such as height, intelligence, or appearance. The framework explicitly classifies this as should not be implemented at the current level of scientific development, but does not use permanent prohibition language, instead recommending reassessment every five years.

WHO Director-General Tedros stated: "EditEthics is not the endpoint but the starting point. Technology develops, and ethical standards must evolve with it. The framework's built-in five-year review mechanism ensures it will not become a dead letter."

Patient advocacy organizations generally welcome the framework. EURORDIS president Avikom Cohen stated: "For families carrying genes for severe hereditary diseases, EditEthics opens a door of hope while establishing necessary safety guardrails."

However, some bioethicists have expressed concern about the framework's openness. Harvard ethics professor Michael Sandel noted: "Setting enhancement editing for five-year review rather than permanent prohibition essentially leaves the door open for future commercialized genetic enhancement."

Currently only a handful of laboratories worldwide possess the technical capability to safely edit human embryo genes. The release of the EditEthics framework marks the formal transition of human embryo gene editing from laboratory discussions to international governance. Whether it can effectively balance technological innovation with ethical boundaries will be truly tested in the coming years.